nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—ABCC2—Cyclosporine—focal segmental glomerulosclerosis	0.102	0.173	CbGbCtD
Sorafenib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.0919	0.156	CbGbCtD
Sorafenib—CYP3A7—Cyclosporine—focal segmental glomerulosclerosis	0.0679	0.115	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Cyclosporine—focal segmental glomerulosclerosis	0.0679	0.115	CbGbCtD
Sorafenib—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.0509	0.0865	CbGbCtD
Sorafenib—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.049	0.0832	CbGbCtD
Sorafenib—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.0411	0.0698	CbGbCtD
Sorafenib—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0342	0.058	CbGbCtD
Sorafenib—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0331	0.0563	CbGbCtD
Sorafenib—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0312	0.053	CbGbCtD
Sorafenib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0199	0.0337	CbGbCtD
Sorafenib—TIE1—endothelium—focal segmental glomerulosclerosis	0.008	0.0651	CbGeAlD
Sorafenib—FLT4—endothelium—focal segmental glomerulosclerosis	0.00661	0.0538	CbGeAlD
Sorafenib—Hyperkeratosis—Cyclosporine—focal segmental glomerulosclerosis	0.00549	0.0633	CcSEcCtD
Sorafenib—Carcinoma—Cyclosporine—focal segmental glomerulosclerosis	0.0052	0.0599	CcSEcCtD
Sorafenib—FLT1—endothelium—focal segmental glomerulosclerosis	0.00514	0.0418	CbGeAlD
Sorafenib—Skin cancer—Cyclosporine—focal segmental glomerulosclerosis	0.00506	0.0584	CcSEcCtD
Sorafenib—KDR—endothelium—focal segmental glomerulosclerosis	0.00435	0.0353	CbGeAlD
Sorafenib—HIPK3—nephron tubule—focal segmental glomerulosclerosis	0.00392	0.0319	CbGeAlD
Sorafenib—KIT—endothelium—focal segmental glomerulosclerosis	0.00385	0.0313	CbGeAlD
Sorafenib—HIPK3—kidney—focal segmental glomerulosclerosis	0.00345	0.028	CbGeAlD
Sorafenib—EPHX2—nephron tubule—focal segmental glomerulosclerosis	0.00336	0.0273	CbGeAlD
Sorafenib—EPHX2—cortex of kidney—focal segmental glomerulosclerosis	0.00287	0.0234	CbGeAlD
Sorafenib—MKNK2—nephron tubule—focal segmental glomerulosclerosis	0.00274	0.0223	CbGeAlD
Sorafenib—UGT1A9—kidney—focal segmental glomerulosclerosis	0.0027	0.0219	CbGeAlD
Sorafenib—Gastrointestinal symptom NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00267	0.0308	CcSEcCtD
Sorafenib—FLT4—cortex of kidney—focal segmental glomerulosclerosis	0.00259	0.0211	CbGeAlD
Sorafenib—FGFR1—cortex of kidney—focal segmental glomerulosclerosis	0.00256	0.0208	CbGeAlD
Sorafenib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.0288	CcSEcCtD
Sorafenib—RALBP1—nephron tubule—focal segmental glomerulosclerosis	0.00248	0.0201	CbGeAlD
Sorafenib—MAP3K7—cortex of kidney—focal segmental glomerulosclerosis	0.00242	0.0197	CbGeAlD
Sorafenib—FLT1—nephron tubule—focal segmental glomerulosclerosis	0.00235	0.0191	CbGeAlD
Sorafenib—RET—kidney—focal segmental glomerulosclerosis	0.00235	0.0191	CbGeAlD
Sorafenib—MKNK2—cortex of kidney—focal segmental glomerulosclerosis	0.00235	0.0191	CbGeAlD
Sorafenib—RAF1—nephron tubule—focal segmental glomerulosclerosis	0.00234	0.019	CbGeAlD
Sorafenib—MKNK1—cortex of kidney—focal segmental glomerulosclerosis	0.00232	0.0188	CbGeAlD
Sorafenib—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.00222	0.0256	CcSEcCtD
Sorafenib—RALBP1—kidney—focal segmental glomerulosclerosis	0.00218	0.0177	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—nephron tubule—focal segmental glomerulosclerosis	0.00217	0.0177	CbGeAlD
Sorafenib—RALBP1—cortex of kidney—focal segmental glomerulosclerosis	0.00212	0.0172	CbGeAlD
Sorafenib—FLT1—kidney—focal segmental glomerulosclerosis	0.00207	0.0168	CbGeAlD
Sorafenib—RAF1—kidney—focal segmental glomerulosclerosis	0.00206	0.0167	CbGeAlD
Sorafenib—FLT1—cortex of kidney—focal segmental glomerulosclerosis	0.00202	0.0164	CbGeAlD
Sorafenib—RAF1—cortex of kidney—focal segmental glomerulosclerosis	0.002	0.0163	CbGeAlD
Sorafenib—EPHB6—cortex of kidney—focal segmental glomerulosclerosis	0.00199	0.0162	CbGeAlD
Sorafenib—KDR—nephron tubule—focal segmental glomerulosclerosis	0.00199	0.0162	CbGeAlD
Sorafenib—STK10—kidney—focal segmental glomerulosclerosis	0.00196	0.0159	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—cortex of kidney—focal segmental glomerulosclerosis	0.00186	0.0151	CbGeAlD
Sorafenib—UGT1A1—kidney—focal segmental glomerulosclerosis	0.00185	0.015	CbGeAlD
Sorafenib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00184	0.0212	CcSEcCtD
Sorafenib—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00177	0.0205	CcSEcCtD
Sorafenib—KIT—nephron tubule—focal segmental glomerulosclerosis	0.00176	0.0143	CbGeAlD
Sorafenib—KDR—kidney—focal segmental glomerulosclerosis	0.00175	0.0142	CbGeAlD
Sorafenib—MAP2K5—cortex of kidney—focal segmental glomerulosclerosis	0.0017	0.0139	CbGeAlD
Sorafenib—KDR—cortex of kidney—focal segmental glomerulosclerosis	0.0017	0.0139	CbGeAlD
Sorafenib—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.0196	CcSEcCtD
Sorafenib—KIT—kidney—focal segmental glomerulosclerosis	0.00155	0.0126	CbGeAlD
Sorafenib—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.0176	CcSEcCtD
Sorafenib—PDGFRB—kidney—focal segmental glomerulosclerosis	0.00151	0.0123	CbGeAlD
Sorafenib—KIT—cortex of kidney—focal segmental glomerulosclerosis	0.00151	0.0123	CbGeAlD
Sorafenib—PDGFRB—cortex of kidney—focal segmental glomerulosclerosis	0.00147	0.012	CbGeAlD
Sorafenib—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.017	CcSEcCtD
Sorafenib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.0164	CcSEcCtD
Sorafenib—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.0014	0.0162	CcSEcCtD
Sorafenib—ABCC4—nephron tubule—focal segmental glomerulosclerosis	0.00137	0.0112	CbGeAlD
Sorafenib—ABCC2—nephron tubule—focal segmental glomerulosclerosis	0.00133	0.0108	CbGeAlD
Sorafenib—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.015	CcSEcCtD
Sorafenib—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.0146	CcSEcCtD
Sorafenib—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.0146	CcSEcCtD
Sorafenib—ABCC4—kidney—focal segmental glomerulosclerosis	0.00121	0.0098	CbGeAlD
Sorafenib—Vismodegib—ALB—focal segmental glomerulosclerosis	0.00118	1	CrCbGaD
Sorafenib—ABCC4—cortex of kidney—focal segmental glomerulosclerosis	0.00117	0.00955	CbGeAlD
Sorafenib—HTR2B—cortex of kidney—focal segmental glomerulosclerosis	0.00117	0.0095	CbGeAlD
Sorafenib—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.0135	CcSEcCtD
Sorafenib—ABCC2—kidney—focal segmental glomerulosclerosis	0.00117	0.00949	CbGeAlD
Sorafenib—ABCC2—cortex of kidney—focal segmental glomerulosclerosis	0.00114	0.00924	CbGeAlD
Sorafenib—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.0124	CcSEcCtD
Sorafenib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.012	CcSEcCtD
Sorafenib—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.012	CcSEcCtD
Sorafenib—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.0119	CcSEcCtD
Sorafenib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.0116	CcSEcCtD
Sorafenib—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000985	0.0114	CcSEcCtD
Sorafenib—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.000968	0.00787	CbGeAlD
Sorafenib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000965	0.0111	CcSEcCtD
Sorafenib—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000944	0.0109	CcSEcCtD
Sorafenib—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.000899	0.00731	CbGeAlD
Sorafenib—CYP2B6—nephron tubule—focal segmental glomerulosclerosis	0.000893	0.00726	CbGeAlD
Sorafenib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000891	0.0103	CcSEcCtD
Sorafenib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000883	0.0102	CcSEcCtD
Sorafenib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000878	0.0101	CcSEcCtD
Sorafenib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000878	0.0101	CcSEcCtD
Sorafenib—CYP2C8—kidney—focal segmental glomerulosclerosis	0.000875	0.00712	CbGeAlD
Sorafenib—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000865	0.00998	CcSEcCtD
Sorafenib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000863	0.00995	CcSEcCtD
Sorafenib—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000861	0.00992	CcSEcCtD
Sorafenib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000861	0.00992	CcSEcCtD
Sorafenib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000856	0.00987	CcSEcCtD
Sorafenib—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000856	0.00987	CcSEcCtD
Sorafenib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00083	0.00958	CcSEcCtD
Sorafenib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000828	0.00955	CcSEcCtD
Sorafenib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000792	0.00914	CcSEcCtD
Sorafenib—CYP3A5—kidney—focal segmental glomerulosclerosis	0.00079	0.00642	CbGeAlD
Sorafenib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000788	0.00909	CcSEcCtD
Sorafenib—CYP2B6—kidney—focal segmental glomerulosclerosis	0.000785	0.00638	CbGeAlD
Sorafenib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000778	0.00898	CcSEcCtD
Sorafenib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000774	0.00893	CcSEcCtD
Sorafenib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000773	0.00891	CcSEcCtD
Sorafenib—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.000769	0.00626	CbGeAlD
Sorafenib—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000735	0.00847	CcSEcCtD
Sorafenib—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000731	0.00844	CcSEcCtD
Sorafenib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000715	0.00825	CcSEcCtD
Sorafenib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00071	0.00819	CcSEcCtD
Sorafenib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000704	0.00812	CcSEcCtD
Sorafenib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000696	0.00803	CcSEcCtD
Sorafenib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00069	0.00796	CcSEcCtD
Sorafenib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000686	0.00791	CcSEcCtD
Sorafenib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000672	0.00775	CcSEcCtD
Sorafenib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00066	0.00761	CcSEcCtD
Sorafenib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000634	0.00731	CcSEcCtD
Sorafenib—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000627	0.00723	CcSEcCtD
Sorafenib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000614	0.00708	CcSEcCtD
Sorafenib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000599	0.0069	CcSEcCtD
Sorafenib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000593	0.00482	CbGeAlD
Sorafenib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000592	0.00683	CcSEcCtD
Sorafenib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000584	0.00674	CcSEcCtD
Sorafenib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000584	0.00674	CcSEcCtD
Sorafenib—CYP2D6—kidney—focal segmental glomerulosclerosis	0.000583	0.00474	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00058	0.00669	CcSEcCtD
Sorafenib—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000571	0.00659	CcSEcCtD
Sorafenib—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00056	0.00646	CcSEcCtD
Sorafenib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00642	CcSEcCtD
Sorafenib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000549	0.00633	CcSEcCtD
Sorafenib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000548	0.00632	CcSEcCtD
Sorafenib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000544	0.00627	CcSEcCtD
Sorafenib—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000534	0.00616	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00051	0.00588	CcSEcCtD
Sorafenib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000499	0.00576	CcSEcCtD
Sorafenib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000493	0.00568	CcSEcCtD
Sorafenib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000487	0.00561	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000483	0.00557	CcSEcCtD
Sorafenib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000483	0.00557	CcSEcCtD
Sorafenib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000479	0.00552	CcSEcCtD
Sorafenib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000479	0.00552	CcSEcCtD
Sorafenib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000478	0.00388	CbGeAlD
Sorafenib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000458	0.00528	CcSEcCtD
Sorafenib—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000445	0.00513	CcSEcCtD
Sorafenib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000443	0.0051	CcSEcCtD
Sorafenib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000443	0.0051	CcSEcCtD
Sorafenib—ABCB1—kidney—focal segmental glomerulosclerosis	0.00042	0.00341	CbGeAlD
Sorafenib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000413	0.00476	CcSEcCtD
Sorafenib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000409	0.00332	CbGeAlD
Sorafenib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000402	0.00463	CcSEcCtD
Sorafenib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000396	0.00457	CcSEcCtD
Sorafenib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000383	0.00442	CcSEcCtD
Sorafenib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00037	0.00427	CcSEcCtD
Sorafenib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000356	0.00411	CcSEcCtD
Sorafenib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000353	0.00407	CcSEcCtD
Sorafenib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000353	0.00407	CcSEcCtD
Sorafenib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000351	0.00405	CcSEcCtD
Sorafenib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000333	0.00384	CcSEcCtD
Sorafenib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.63e-05	0.000131	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.63e-05	0.000131	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	2.63e-05	0.000131	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.62e-05	0.000131	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.61e-05	0.00013	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—LIPC—focal segmental glomerulosclerosis	2.61e-05	0.00013	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.6e-05	0.00013	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.59e-05	0.000129	CbGpPWpGaD
Sorafenib—MKNK1—Disease—TGFB1—focal segmental glomerulosclerosis	2.59e-05	0.000129	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.58e-05	0.000129	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.58e-05	0.000129	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.56e-05	0.000128	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	2.55e-05	0.000127	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.55e-05	0.000127	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.55e-05	0.000127	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.54e-05	0.000127	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.52e-05	0.000126	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.52e-05	0.000126	CbGpPWpGaD
Sorafenib—BRAF—Disease—NOS2—focal segmental glomerulosclerosis	2.48e-05	0.000124	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.47e-05	0.000124	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—LPL—focal segmental glomerulosclerosis	2.47e-05	0.000123	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.46e-05	0.000123	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.46e-05	0.000123	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.45e-05	0.000122	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.43e-05	0.000122	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD40LG—focal segmental glomerulosclerosis	2.43e-05	0.000121	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.4e-05	0.00012	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.39e-05	0.000119	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.34e-05	0.000117	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.33e-05	0.000116	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.33e-05	0.000116	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	2.32e-05	0.000116	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.32e-05	0.000116	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.32e-05	0.000116	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CTGF—focal segmental glomerulosclerosis	2.3e-05	0.000115	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.3e-05	0.000115	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.29e-05	0.000114	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.29e-05	0.000114	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	2.27e-05	0.000113	CbGpPWpGaD
Sorafenib—KIT—Disease—NOS2—focal segmental glomerulosclerosis	2.26e-05	0.000113	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.25e-05	0.000112	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.25e-05	0.000112	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.25e-05	0.000112	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.24e-05	0.000112	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.24e-05	0.000112	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.24e-05	0.000112	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.23e-05	0.000111	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.23e-05	0.000111	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.22e-05	0.000111	CbGpPWpGaD
Sorafenib—RAF1—Disease—LPL—focal segmental glomerulosclerosis	2.2e-05	0.00011	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.2e-05	0.00011	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.19e-05	0.000109	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.19e-05	0.000109	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOS2—focal segmental glomerulosclerosis	2.14e-05	0.000107	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS2—focal segmental glomerulosclerosis	2.14e-05	0.000107	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.13e-05	0.000107	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.13e-05	0.000106	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	2.12e-05	0.000106	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.12e-05	0.000106	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.12e-05	0.000106	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.11e-05	0.000105	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.11e-05	0.000105	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.1e-05	0.000105	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.1e-05	0.000105	CbGpPWpGaD
Sorafenib—BRAF—Disease—SERPINE1—focal segmental glomerulosclerosis	2.09e-05	0.000104	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.09e-05	0.000104	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.09e-05	0.000104	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.07e-05	0.000103	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.05e-05	0.000102	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.03e-05	0.000101	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.03e-05	0.000101	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2e-05	0.0001	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2e-05	9.97e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.98e-05	9.89e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.98e-05	9.87e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.98e-05	9.86e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	1.94e-05	9.68e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—LIPC—focal segmental glomerulosclerosis	1.93e-05	9.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS2—focal segmental glomerulosclerosis	1.93e-05	9.62e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.92e-05	9.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.92e-05	9.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.92e-05	9.6e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.92e-05	9.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.92e-05	9.58e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.92e-05	9.58e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.92e-05	9.57e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.91e-05	9.56e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.9e-05	9.5e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—SERPINE1—focal segmental glomerulosclerosis	1.9e-05	9.5e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—LPL—focal segmental glomerulosclerosis	1.89e-05	9.45e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—LPL—focal segmental glomerulosclerosis	1.89e-05	9.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.89e-05	9.41e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	1.89e-05	9.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.87e-05	9.34e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—TGFB1—focal segmental glomerulosclerosis	1.82e-05	9.09e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.82e-05	9.09e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.82e-05	9.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.82e-05	9.06e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.81e-05	9.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—SERPINE1—focal segmental glomerulosclerosis	1.81e-05	9.01e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—SERPINE1—focal segmental glomerulosclerosis	1.8e-05	8.99e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.78e-05	8.89e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.78e-05	8.86e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.77e-05	8.82e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.76e-05	8.8e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.76e-05	8.78e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.73e-05	8.65e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.73e-05	8.65e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.73e-05	8.62e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.72e-05	8.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS2—focal segmental glomerulosclerosis	1.72e-05	8.57e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.71e-05	8.53e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CTGF—focal segmental glomerulosclerosis	1.7e-05	8.48e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.7e-05	8.47e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	1.66e-05	8.29e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.65e-05	8.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.64e-05	8.21e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.64e-05	8.19e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.64e-05	8.17e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	1.63e-05	8.15e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.63e-05	8.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—SERPINE1—focal segmental glomerulosclerosis	1.62e-05	8.1e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AGT—focal segmental glomerulosclerosis	1.62e-05	8.08e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AGT—focal segmental glomerulosclerosis	1.62e-05	8.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.62e-05	8.06e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	1.61e-05	8.02e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.6e-05	7.99e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.6e-05	7.99e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—LPL—focal segmental glomerulosclerosis	1.59e-05	7.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.59e-05	7.92e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.56e-05	7.81e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.56e-05	7.79e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.56e-05	7.78e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.56e-05	7.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.54e-05	7.69e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.53e-05	7.63e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.52e-05	7.58e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.52e-05	7.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.48e-05	7.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.48e-05	7.38e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.47e-05	7.33e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.46e-05	7.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.46e-05	7.28e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	1.46e-05	7.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—SERPINE1—focal segmental glomerulosclerosis	1.45e-05	7.22e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	1.44e-05	7.18e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.42e-05	7.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.41e-05	7.03e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	1.37e-05	6.86e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.37e-05	6.84e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.37e-05	6.82e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AGT—focal segmental glomerulosclerosis	1.36e-05	6.8e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.35e-05	6.74e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	1.34e-05	6.69e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.33e-05	6.65e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.33e-05	6.65e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.33e-05	6.65e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	1.33e-05	6.63e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.33e-05	6.63e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.32e-05	6.61e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—focal segmental glomerulosclerosis	1.32e-05	6.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.32e-05	6.57e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.32e-05	6.57e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.31e-05	6.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.3e-05	6.5e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	1.28e-05	6.41e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.26e-05	6.31e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.26e-05	6.3e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.26e-05	6.28e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.25e-05	6.25e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—focal segmental glomerulosclerosis	1.24e-05	6.2e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—focal segmental glomerulosclerosis	1.24e-05	6.2e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.22e-05	6.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.22e-05	6.07e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—focal segmental glomerulosclerosis	1.2e-05	6e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.2e-05	5.97e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.18e-05	5.9e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	1.18e-05	5.89e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—LPL—focal segmental glomerulosclerosis	1.18e-05	5.88e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	1.17e-05	5.84e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.15e-05	5.76e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	1.15e-05	5.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—focal segmental glomerulosclerosis	1.14e-05	5.69e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.14e-05	5.68e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—focal segmental glomerulosclerosis	1.14e-05	5.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.14e-05	5.67e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	1.14e-05	5.67e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.13e-05	5.65e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.12e-05	5.6e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.11e-05	5.56e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.09e-05	5.43e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.08e-05	5.41e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.08e-05	5.41e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.08e-05	5.38e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	1.05e-05	5.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.05e-05	5.24e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—focal segmental glomerulosclerosis	1.05e-05	5.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—focal segmental glomerulosclerosis	1.02e-05	5.11e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.02e-05	5.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.02e-05	5.09e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.02e-05	5.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.01e-05	5.05e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AGT—focal segmental glomerulosclerosis	1.01e-05	5.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	1e-05	4.99e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	9.97e-06	4.97e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	9.85e-06	4.91e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.69e-06	4.83e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.66e-06	4.82e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.33e-06	4.66e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.24e-06	4.61e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.21e-06	4.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—focal segmental glomerulosclerosis	9.13e-06	4.56e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	8.9e-06	4.44e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	8.77e-06	4.38e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	8.74e-06	4.36e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.7e-06	4.34e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	8.68e-06	4.33e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	8.53e-06	4.26e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.41e-06	4.2e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.41e-06	4.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.3e-06	4.14e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	8.18e-06	4.08e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	8.11e-06	4.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.98e-06	3.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.96e-06	3.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.76e-06	3.87e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—focal segmental glomerulosclerosis	7.73e-06	3.86e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	7.72e-06	3.85e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	7.61e-06	3.8e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	7.56e-06	3.77e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	7.43e-06	3.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.17e-06	3.58e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.11e-06	3.55e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	7e-06	3.49e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	6.94e-06	3.46e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	6.93e-06	3.46e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.84e-06	3.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.7e-06	3.34e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	6.54e-06	3.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.39e-06	3.19e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	5.93e-06	2.96e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	5.84e-06	2.92e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	5.7e-06	2.85e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.52e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	5.37e-06	2.68e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	5.35e-06	2.67e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	5.33e-06	2.66e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	4.58e-06	2.28e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	4.55e-06	2.27e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	3.51e-06	1.75e-05	CbGpPWpGaD
